New Biomarkers in the Prediction of Chemotherapy-induced Cardiotoxicity.
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Cardiotoxicity
- Sponsor
- Cardiology Prague
- Enrollment
- 200
- Locations
- 2
- Primary Endpoint
- Early detection of the cardiotoxic effect of chemotherapy using new biomarkers
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
Early detection and thus rapid therapy of cardiotoxicity related to chemotherapy are essential for restoring cardiovascular function. The complete recovery of the cardiovascular system decreases with time to identify the presence of cardiotoxic damage. The project aims to define new biomarkers for the early detection of cardiotoxicity in patients treated with chemotherapy.
Detailed Description
The most effective approach to minimizing the consequences of cardiotoxicity of oncological treatment is its early identification, adjustment of oncological treatment (change of procedure, dose, drugs), and immediate initiation of cardiovascular therapy. However, the current standard for monitoring the cardiovascular system in cancer patients identifies cardiotoxicity only if functional impairment has already occurred, which precludes any chance of effective prevention. The aim of the project is to identify new biomarkers for the early detection of the cardiotoxic effect of chemotherapy in women with breast cancer.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Breast cancer
- •Chemotherapy with a known cardiotoxic side effect
Exclusion Criteria
- •Known cardiovascular disease
Outcomes
Primary Outcomes
Early detection of the cardiotoxic effect of chemotherapy using new biomarkers
Time Frame: one year follow-up.
Echocardiography and MRI detection of cardiotoxic effect of chemotherapy - dysfunction of left ventricle, arrythmias, hypertension